akampioneer.com
Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting | the akampioneer
http://akampioneer.com/company-news/company-news-anergis-presents-sustained-efficacy-data-from-its-allert-phase-iib-trial-at-the-aaaai-annual-meeting.html
Company News: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting. Monday, February 23, 2015. Contiguous Overlapping Peptide allergy immunotherapeutic AllerT confirms sustained efficacy in the second year following treatment. A company developing novel and proprietary ultra-fast allergy immunotherapeutics, presented detailed data from the Phase IIb trial of its birch pollen allergy immunotherapeutic AllerT in two separate scientific posters at the AAAAI (.
swissbiotech.org
News | swissbiotech.org
http://www.swissbiotech.org/news
Swiss Biotech - NTN. Legal Framework and Swiss Policies. Health Biotech / Drug Development. Finance and Legal Platform. Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies. GlobeNewswire, 02.09.2016. Die Schweiz als grosser Globalisierungs-Profiteur. Neue Zürcher Zeitung , 02.09.2016. 1360 Euro Gewinn je Schweizer Kein Nullsummenspiel. Kranke Mäuse halten Distanz. Interpharma, 01.09.2016. SIKA ERÖFFNET MÖRTEL-TECHNOLOGIEZENTRUM IN DEUTSCHLAND. Togeth...
blueocean-ventures.com
Blue Ocean Ventures
http://www.blueocean-ventures.com/portfolio.html
SENSIMED SA is an emerging medical device company with its principal focus on the design, development, and commercialization of integrated micro-systems for medical diagnosis and treatment monitoring in the area of ophthalmology. AUGURIX SA based in Geneva, is in the business of screening, diagnosing and monitoring one of the most under-diagnosed medical conditions worldwide: Gluten intolerance (Celiac disease). AIMAGO SA develops, validates and commercializes easy-to-use imaging technologies for visuali...
immunologyresearch.ch
Liens - Service d'immunologie et allergie - CHUV
http://www.immunologyresearch.ch/ial_home/ial-patients-et-familles/ial-professionnels-sante-liens.htm
Les activités du CHUV. Allergies, maladies infectieuses et immunologie. Vaccination et médecine des voyages. Bouche, dents et visage. Chirurgie plastique et de la main. Stomatologie et médecine dentaire. Centre de la prostate. Centre des tumeurs thoraciques. Soins palliatifs et de support. Cerveau, colonne vertébrale et système neveux. Cerveau, colonne vertébrale et système nerveux (neurosciences cliniques). Centre de la mémoire. Centre sur le sommeil (CIRS). Endocrinologie, diabète et métabolisme. Soins...
akampioneer.com
Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial | the akampioneer
http://akampioneer.com/company-news/company-news-anergis-announces-completion-of-treatment-in-allert-phase-ii-dose-ranging-trial.html
Company News: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial. Wednesday, April 1, 2015. 213 patients included in trial of novel ultra-fast allergy immunotherapeutic. Posted in Company News. You can follow any responses to this entry through the RSS 2.0. Both comments and pings are currently closed. Laquo; Company News: ISA Pharmaceuticals Granted European Patent for the Intradermal Administration of ISA101. Company News: Curetis Appoints Christopher M. Bernard as Chie...
vincicapital.ch
Investments - Vinci Capital
http://www.vincicapital.ch/en-us/pme_kmu_sme/portfolio.html
Quick accesses for handicapped people. Medical Technology and Healthcare. BACK TO HOME PAGE. A significant presence across Switzerland. A significant presence across Switzerland. VINCI CAPITAL - EPFL Innovation Park, Bât. C - CH-1015 Lausanne - Tel 41 (0)58 201 17 81 - info@vincicapital.ch. VINCI CAPITAL - EPFL Innovation Park, Bât. C- CH-1015 Lausanne - Tel 41 (0)58 201 17 81.
vincicapital.ch
Start Seite - Vinci Capital
http://www.vincicapital.ch/de-ch/pme_kmu_sme/home.html
Schneller Zugang für behinderte Personen. Suche auf der Website. Abonnieren Sie unseren Newsletter. Folgen Sie uns auf LinkedIn. Asic Robotics AG is a leading supplier of high-tech mechanical engineering for special purposes and industrial robots. Evolva SA is a Swiss-headquartered (Allschwil/Basel), international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. Develops and commercializes archiving and r...
pactt.ch
Start-up companies |
http://www.pactt.ch/sample-page/industry/projects-to-be-developed-in-start-up
Mission & objectives. Collaborate with other academic institutions. Learn about Intellectual property. Disclose an invention or a software. Create a start-up company. Technologies available for licensing. Confidentiality Agreement Non-Disclosure Agreement (NDA). Material Transfer Agreement (MTA). Disclosure forms IDF or SwDF. Where to find us. Technologies available for licensing. Apoxis SA, now Onxeo. PACTT - Technology Transfer Office UNIL-CHUV. Rue du Bugnon 21. 41 21 314 59 72.
drugdevelopment.unige.ch
Partners
http://drugdevelopment.unige.ch/index.php/partners
Management of Clinical Trials. Target skills and competencies. Target skills and competencies. You are here: .